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Abstract:
Background: Individual genetic differences affecting thyroid hormone production may lead to treatment resistance in hypothyroid patients. Identification
of these differences may lead to better treatments. Objective: To review the current literature examining the effect of the Thr92Ala DIO2 polymorphism
on thyroid hormonogenesis. Methods: Literature search of scholarly databases for primary human studies investigating the impact of the DIO2 Thr92Ala
polymorphism on hypothyroidism was performed. Results and Conclusion: The Thr92Ala SNP of the DIO2 gene has been shown to negatively impact
the conversion of inactive T4 to the active T3. Hypothyroid carriers of this SNP treated solely with levothyroxine (LT4) may have suboptimal T3 levels
leading to poorer outcomes.
Introduction:
Thyroid hormonogenesis is a tightly regulated and
complex process crucial for normal metabolic
function. Insufficient production of thyroid
hormones leads to hypothyroidism which is more
prevalent in Caucasians, women, and those over 60
years of age [1]. While the thyroid produces
predominantly inactive T4 (thyroxine), the
deiodinase enzymes are responsible for the
conversion to the active T3 (triiodothyronine) via
deiodination of the outer ring.
The type-II iodothyronine deiodinase enzyme (D2)
coded by the deiodinase-2 gene (DIO2) has a
higher affinity for T4 than other deiodinase
enzymes, therefore it is responsible for the
majority of T3 production [2]. Insufficient enzyme
cofactors and genetics may affect deiodinase
activity leading to lower levels of T3. Multiple
single nucleotide polymorphisms (SNPs) in the
deiodinase genes have been reviewed in the
literature[3] and presence of these SNPs may lead to
inadequate management in patients prescribed
LT4, the standard pharmacological treatment of
hypothyroidism [4]. The DIO2 Thr92Ala SNP,
commonly found in 12-36% of the population, is
associated with a threonine (thr) to alanine (ala)
substitution at the 92nd codon and this substitution
has been shown to affect the activity of the enzyme
[5]. This research reviews the current literature
regarding the DIO2 Thr92Ala SNP and its impact
on deiodinase 2 enzyme activity and peripheral
conversion of T4 to T3.
Conclusion:
This review examined the impact of the Thr92Ala SNP on DIO2 activity on T4 to T3
peripheral conversion in human subjects. This SNP results in an alanine substitution
for threonine at the 92nd codon, which greatly reduces the ability of the DIO2
enzyme to properly convert T4 to T3. Ala carriers showed significant decreases in T3
levels compared to Thr carriers, with Ala homozygotes the most affected. While more
studies are needed, genotyping patients for DIO2 Thr92Ala SNP may identify those
ask risk for standard treatment failure leading to early use of mixed T4/T3
medications and nutritional supplementation of cofactors to support optimal
peripheral conversion.
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Results:
Fig. 2 – Post thyroidectomy levels of FT3 were lower
in those that were homozygous (Ala/Ala) and
heterozygous (Thr/Ala) for the Thr92Ala
polymorphism than in those that were homozygous
wild type. Reproduced from Fig 1d: Castagna et al. [6]
Fig. 3 – Change in serum T3 levels after TRH administration were
blunted in those that were homozygous (Ala/Ala) for the Thr92Ala
polymorphism compare to those that were homozygous wild type
(Thr/Thr). Reproduced from Fig 2: Butler et al. [7]
Fig. 4 – A 2016 population study by Wouters, et al. found no statistical differences in thyroid parameters for female LT4 users
matched for age and BMI in each of the different genotypes, but they did not analyze male LT4 users. Reproduced and
truncated from Table 3: Wouters, et al.[8]
Methods:
A search of the following databases; PubMed,
Science Direct and Google Scholar, was performed
using the following search terms: thyroid, thyroid
function, hormones, serum T4, serum T3, thyroid
stimulating hormone, single nucleotide
polymorphism, homeostasis, HPT axis, deiodinase
gene, Thr92Ala. Articles were included if they
were primary studies, used human subjects, were
published between 2009 – 2018, and focused solely
on the DIO2 Thr92Ala polymorphism and
hypothyroidism.
